Navigation Links
Benda Pharmaceutical Reports Third Quarter 2008 Financial Results
Date:11/18/2008

proved to $4.7 million, or $0.05 per diluted share, from a net loss of $7.3 million, or $0.06 per diluted share, in the first nine months of 2007. Net loss in the first nine months of 2008 includes the impact of approximately $3.3 million in interest expenses related to the Company's outstanding convertible notes and the $1.4 million payment to investors related to the timing of the effectiveness of its registration statement on Form S-1. The Company was granted effectiveness on the S-1 filing and does not anticipate further penalty payments related to this S-1 filing going forward.

Three Months Ended September 30, 2008

Revenue in the third quarter of 2008 decreased 12.2% to $6.6 million from $7.6 million in the third quarter of 2007, primarily reflecting increased sales at Benda Ebei, offset by sales declines at SiBiono related to the Company's reorganization of personnel in the department. Benda management concluded the reorganization during the third quarter of 2008, and SiBiono has resumed production and sales. In the third quarter of 2008, the Company sold 3,021 vials of Gendicine, a sequential increase from sales of 1,087 vials sold in the first quarter of 2008 and 2,439 vials sold in the second quarter of 2008.

Gross profit in the third quarter of 2008 was $2.4 million, a decrease of 36.1% from $3.8 million in the third quarter of 2007. Gross margin was 36.5%, compared with 50.1% in the same period of 2007. The decline in gross margin was primarily due to a re-engineering of SiBiono's production department, which affected the sales of Gendicine. However, management believes that the re-engineering will lead to revenue growth in the coming quarters.

Operating income in the third quarter of 2008 decreased to $0.6 million from $1.7 million in the third quarter of 2007. Operating expense in the third quarter was approximately $1.8 million, compared with $2.1 million in the thi
'/>"/>

SOURCE Benda Pharmaceutical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Benda Pharmaceutical Files Amendment To Form S-1
2. Anadys Pharmaceuticals to Present at the Needham Focus on Infectious Disease Conference
3. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
4. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. NanoBio to Give Four Scientific Presentations at Upcoming National Meeting of Pharmaceutical Scientists
7. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. White Paper Details How DNA Sequencing Services Can Prevent Cleanroom Shutdowns at Medical Device and Pharmaceutical Manufacturers
10. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
11. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Genomics and Proteomics Analytical Instruments Market 2014-2018" report ... Genomics is the study of the ... of the structure and functions of proteomes or sets ... and technology. Genomics involves the mapping of genes and ...
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... 24, 2014  Neogen Corporation (Nasdaq: NEOG ... its potential revenue from new rodenticide research are premature. ... analysts on July 22, 2014, Neogen,s CEO commented about ... research. "It was my intent Tuesday at ... of a new type of rodenticide, but certainly not ...
(Date:7/24/2014)... Toronto, Canada (PRWEB) July 24, 2014 ... for Optimizing Dose Escalation in First in Human Studies” ... to make better go/no-go decisions. , With increasing R&D ... market, pharmaceutical companies need to maximize the knowledge collected ... go/no-go decisions and improve success in late stage development. ...
Breaking Biology Technology:Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... , SAN DIEGO, June 8 , , ... 51 speakers and panelists discussing life sciences and the business relationships ... WHAT: , CALAsia is an international 2-day forum that ... and the Asia Pacific region to identify, explore, and further trans-Pacific ...
... on Testing OVAR Effectiveness , , PITTSBURGH, June ... ), manufacturers of noninvasive medical evaluation equipment used ... disorders, said today that the University of Michigan ... has purchased and installed its I-Portal(R) NOTC (Neuro-Otologic Test ...
... 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA ... that it,begins the production of a vaccine against influenza A (H1N1) ... to the company on June 8, 2009. , ... ,In,the midst of a global outbreak and transmission of H1N1, our ...
Cached Biology Technology:BIOCOM's Inaugural CALAsia Forum 'Bridging the Pacific' 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 3Sinovac Begins the Production of Influenza A (H1N1) Vaccine 2Sinovac Begins the Production of Influenza A (H1N1) Vaccine 3
(Date:7/24/2014)... is available in German . ... 300 million asthma sufferers worldwide, a further 600 million ... of the global population contending with allergic rhinitis (allergic ... also affect other organs and parts of the body ... intestine (in the form of inflammatory bowel diseases such ...
(Date:7/24/2014)... is available in German . ... recognize and respond to threats to health, and to ... understanding of the mechanism underlying immunologic memory, however, has ... converged to support the hypothesis that the persistence of ... with stem-cell-like potential. Until now, there was no conclusive ...
(Date:7/23/2014)... of identical twins has found that early reading skill ... the journal Child Development , was conducted by ... London. , "Since reading is an ability that can ... according to Stuart J. Ritchie, research fellow in psychology ... "Early remediation of reading problems might aid not only ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Experiments prove 'stemness' of individual immune memory cells 2Experiments prove 'stemness' of individual immune memory cells 3Stronger early reading skills predict higher intelligence later 2
... (LOS ANGELES, CA) -- The Disability Rights Legal Center ... civil rights of people with disabilities, has recognized Ossur, ... non-invasive orthopaedic products and services, with the Charles D. ... of Prosthetics for Ossur Americas, accepted the award on ...
... soft drink is 20 ounces and contains 17 teaspoons of ... fruit drinks are more erosive than hydrochloric or sulfuric acidwhich ... acids found in soda and citrus juice promote tooth erosion, ... the enamel. Once tooth enamel is lost, it,s gone forever. ...
... INDIANAPOLIS Although its been over a decade since ... the blood repairing and replacing the cells that line ... EPCs are now being studied as biomarkers to assess ... agents for vascular regeneration. Researchers from ...
Cached Biology News:Disability Rights Legal Center honors Ossur 2Drink brewed tea to avoid tooth erosion 2Understanding how oxidative stress impairs endothelial progenitor cell function 2
... high experimental throughput, minimum input of ... 4 up to 16 culture vessels ... users with proven fermentation results when ... fungi or any other microbial application. ...
... Experion system, 100-120 and 220-240 V, is ... steps of gel-based electrophoresis, including some data ... is used for protein analysis (it does ... RNA analysis). The system includes the electrophoresis ...
... in the submicron range are part of ... and control of particle size is important ... can reliably detect the component populations in ... Particle Size Analyzer uses Photon Correlation Spectroscopy ...
... Binding: High, 400 ng IgG/cm 2 ... Interaction: Hydrophobic/Ionic , Performance Certified: Well-to-Well, CV ... Maximum Well Volume: 360 µl , Packaging: ... ,Features, Special optically clear polystyrene formulation , ...
Biology Products: